Denervation treatment of affective disorders.
It was assumed that affective disorders of any aetiology are systemised adrenergic neuronal denervative conditions. If so, short-term pharmacological denervation must result in completion of pre-existing partial neuronal denervation and in subsequent postdenervation supersensitivity and neuronal recovery. Clinically controlled trials in depressive syndromes of various aetiology support this hypothesis.
D001921:Brain / Q000503:physiopathology; D003863:Depression / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006185:Habituation, Psychophysiologic; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use*; D008875:Middle Aged; D008959:Models, Neurological; D009474:Neurons / Q000503:physiopathology; D009475:Neurons, Afferent / Q000503:physiopathology; D012075:Remission, Spontaneous
D008750:Methyldopa